Business and Capital Alliance with Medipal and Clinical Development by a U.S. Joint Venture
First written in FY2018-Q2. 4 of 6 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019RestatedAnnual report
「Among these activities, we will give top priority to the early overseas development of lysosomal disease programs using J-Brain Cargo®, including JR-141, while utilizing JCR USA, Inc., which was established last January.」
The company reconfirmed its policy of using JCR USA, Inc., established under its business and capital alliance with Medipal, for overseas clinical development. - FY2019-Q2RestatedAnnual report
「We are considering the global rollout of all these lysosomal disease enzyme replacement therapies. Clinical development in the United States will proceed through JCR USA, Inc., a joint venture established in the United States with メディパルホールディングス in January this year.」
The company reconfirmed the framework for advancing U.S. clinical development of enzyme replacement therapies for lysosomal diseases through JCR USA, Inc., its U.S. joint venture with Medipal Holdings Corporation. - FY2019-Q1RestatedAnnual report
「We are considering the global rollout of all lysosomal disease enzyme replacement therapies. Clinical development in the United States is scheduled to proceed through JCR USA, Inc., a joint venture established in the United States with メディパルホールディングス in January this year.」
The company reconfirmed the framework for advancing U.S. clinical development of enzyme replacement therapies for lysosomal diseases through JCR USA, Inc., its U.S. joint venture with Medipal Holdings Corporation. - FY2018RestatedAnnual report
「In addition, as a base for the global development of our pipeline products, we established the U.S. joint venture JCR USA, Inc. with Medipal Holdings Corporation on 1 January of this year.」
The company reconfirmed the establishment of JCR USA, Inc. in January 2018 and the framework for U.S.-based clinical development under its business and capital alliance with Medipal. - FY2018-Q3AchievedAnnual report
「In addition, to centrally manage the early-stage clinical development of JR-141 and JR-162 in the United States, we established the U.S. joint venture JCR USA,Inc. with Medipal Holdings Corporation on 1 January of this year.」
The company reported reaching the implementation stage for the previously agreed U.S. joint venture by establishing JCR USA,Inc. on 1 January 2018. - FY2018-Q2First statedAnnual report
「On 21 September of this year, we entered into a business and capital alliance agreement with Medipal Holdings Corporation. The alliance covers the conduct of clinical development for various drug candidates through a joint venture to be established in the United States by the two companies, as well as the acquisition of our shares by Medipal Holdings Corporation.」
The company entered into a business and capital alliance agreement with Medipal, covering clinical development of drug candidates through a U.S. joint venture and the acquisition of the company’s shares by Medipal.